Novo Integrated Sciences Bilan de santé

Santé financière contrôle des critères 2/6

Novo Integrated Sciences possède un total de capitaux propres de $9.7M et une dette totale de $2.6M, ce qui porte son ratio d'endettement à 26.4%. Son actif total et son passif total sont $35.3M et de $25.7M.

Informations clés

26.4%

Ratio d'endettement

US$2.55m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$1.54m
Fonds propres	US$9.66m
Total du passif	US$25.66m
Total des actifs	US$35.33m

Mises à jour récentes de la santé financière

Recent updates

Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch

Jul 11

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

Apr 18

Novo Integrated Sciences prices 4M unit public offering at $.50/unit

Oct 14

Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue

Jul 11

Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Nov 23

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Aug 07

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Mar 02

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NVOS ( $6.2M ) ne couvrent pas ses passifs à court terme ( $22.7M ).

Passif à long terme: Les actifs à court terme de NVOS ( $6.2M ) dépassent ses passifs à long terme ( $3.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de NVOS ( 10.5% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de NVOS est passé de 9.8% à 26.4% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: NVOS dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: NVOS dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 31.7 % chaque année

Novo Integrated Sciences Bilan de santé

Santé financière contrôle des critères 2/6

Informations clés

Mises à jour récentes de la santé financière

Novo Integrated Sciences Intends to Request Hearing Before Nasdaq Hearing Panel

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. Receives A Notification Letter from the Nasdaq Stock Market, LLC

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Novo Integrated Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Recent updates

Novo Integrated Sciences, Inc.(OTCPK:NVOS) dropped from S&P TMI Index

Novo Integrated Sciences, Inc.(OTCPK:NVOS) dropped from NASDAQ Composite Index

Novo Integrated Sciences, Inc., Annual General Meeting, Nov 22, 2024

Novo Integrated Sciences Intends to Request Hearing Before Nasdaq Hearing Panel

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) acquired Ophir Collection, Llc.

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.58 loss in 2Q 2023)

Novo Integrated Sciences, Inc. Announces Executive Changes

Novo Integrated Sciences, Inc. Receives A Notification Letter from the Nasdaq Stock Market, LLC

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Novo Integrated Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) announces an Equity Buyback for $5 million worth of its shares.

Novo Integrated Sciences, Inc.'s IoNovo for Kids receives Registration Number and Regulatory Approval by Turkey’s Ministry of Health

Novo Integrated Sciences, Inc.’ IoNovo Iodine Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health

Novo Integrated Sciences, Inc., Annual General Meeting, Sep 29, 2023

New minor risk - Revenue size

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.13 loss in 3Q 2022)

Novo Integrated Sciences, Inc. Appoints Vivek Sethi as Principal Financial Officer

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.067 loss in 1Q 2022)

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

High number of new and inexperienced directors

Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Novo Integrated Sciences Receives A Notification Letter from Nasdaq Regarding Minimum Bid Price Requirements

High number of new and inexperienced directors

Novo Integrated Sciences, Inc. has completed a Composite Units Offering in the amount of $2 million.

Novo Integrated Sciences, Inc. has completed a Composite Units Offering in the amount of $2 million.

Novo Integrated Sciences prices 4M unit public offering at $.50/unit

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.016 loss in 3Q 2021)

Novo Integrated Sciences, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2022

Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue

Novo Integrated Sciences, Inc., Annual General Meeting, Aug 19, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.056 loss in 2Q 2021)

Less than half of directors are independent

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) agreed to acquire Seven Pharmacies in the United States.

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.016 loss per share (vs US$0.004 loss in 3Q 2020)

Principal Financial Officer & Principal Accounting Officer Sterling Jimenez has left the company

Principal Financial Officer & Principal Accounting Officer has left the company

Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.022 loss in 2Q 2020)

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Novo Integrated Sciences Announces Three New Independent Directors Appointments to Its Board of Directors and Formation of an Audit Committee

Novo Integrated Sciences, Inc. Announces Executive Changes

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines